Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Fabry disease
- Metabolic defect - accumulation of GL-3
- GL-3 deposits in vascular endothelium
- Progression in affected males
- Inheritance
- Progression in affected females
- Multisystemic manifestations
- Angiokeratomas
- Corneal whorls
- Diagnosis of Fabry disease
- Differential diagnosis
- Classical presentation Fabry disease
- Classical presentation - MRI
- Classical presentation - kidney biopsy (1)
- Classical presentation - kidney biopsy (2)
- Zebra bodies
- Zebra bodies in EM
- Less severe presentation in an older brother
- Renal biopsy findings
- Involvement of tubules
- Zebra bodies in kidney glomerulus
- Heavy dense deposits in EM
- Fabry disease: affected females
- Foamy cytoplasmic inclusion
- Foamy cytoplasmic inclusion - higher power view
- Cardiac involvement (1)
- Cardiac involvement (2)
- Cardiac involvement (3)
- Summary of kidney pathology
- Treatment of Fabry disease with renal involvement
- Renal transplant
- Enzyme therapy in transplant
- End stage renal disease in Fabry
- Patient survival on dialysis
- Enzyme therapy in dialysis
- Enzyme replacement therapy - drugs
- ERT - trials
- Phase 3 - complete endothelial clearance
- GL-3 cleared from kidney
- ERT (1)
- ERT (2)
- Similarities of Fabry disease and diabetes
- Fabry and diabetic nephropathy - management
- Fabry disease - conclusions
Topics Covered
- Diagnosis of Fabry disease
- Metabolic defect: GL-3 accumulation
- Multi-systemic manifestations
- Case examples
- Kidney pathology in Fabry disease
- Enzyme therapy
- Dialysis and transplantation
- Analogy to diabetic nephropathy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Warnock, D. (2007, October 1). Fabry disease: alfa-galactosidase A deficiency and enzyme replacement therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/IYBN9461.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David Warnock has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide